BeiGene Announces Presentations on BGB-283 and Other Pipeline Agents at the 2016 American Association for Cancer Research Annual Meeting

WALTHAM, Mass., March 16, 2016 -- BeiGene, Ltd. (NASDAQ:BGNE) (“BeiGene”), a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncological drugs for the treatment of cancer, today announced that its abstract highlighting the Phase I study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors has been selected for oral presentation in a Clinical Trials Plenary Session at the 2016 American Association for Cancer Research (AACR) Annual Meeting. In addition, BeiGene will present eight posters related to its pipeline agents including BGB-A317 (PD-1 antibody), BGB-3111 (BTK inhibitor), and BGB-283 during this AACR meeting. The AACR Annual Meeting will take place April 16–20 in New Orleans, Louisiana, United States. Details for the oral presentation and posters are provided below. Further details can be found on AACR website.

Oral Presentation, Abstract # CT005

Title: Phase I study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors

Authors: Jayesh Desai, Hui Gan, Catherine Barrow, Michael B. Jameson, Grant Mcarthur, Ben Tran, Michael Lam, Laird Cameron, Andrew Weickhardt, Jason Yang, Lai Wang, Zhen Qin, Lusong Luo, Ben Solomon

Presenter: Dr. Jayesh Desai
Session: Precision Medicine Early Clinical Trials
Date: Sunday, April 17, 2016
Time: 4:15 - 6:00 PM CDT
Location: La Nouvelle Ballroom, Room 297, Morial Convention Center

Poster Presentations:
Abstract #342: Liu Y. et al., BGB-283, a slow-off inhibitor of RAF dimers, differentiates from vemurafenib in MAPK signaling inhibition. Sun, Apr 17, 1:00 - 5:00 PM

Abstract #1230: Tang Z. et al.,BGB-283: a novel RAF Dimer inhibitor, displays potent antitumor activity in HCC patient derived xenograft models. Mon, Apr 18, 8:00 AM - 12:00 PM

Abstract #1298: Sun Z. et al.,CD40L-CD40 signaling on B-cell lymphoma response to BTK inhibitors. Mon, Apr 18, 8:00 AM - 12:00 PM

Abstract #2226: Zhang T. et al.,Anti-human PD-1 antibody BGB-A317 exhibits potent immune cell activation. Mon, Apr 18, 1:00 - 5:00 PM

Abstract #4260: Wu X. et al.,3D colorectal cancer organoids as preclinical models for assessment of activity of RAF inhibitor BGB-283. Tue, Apr 19, 1:00 - 5:00 PM.

Abstract #4698: Zhao Y. et al.,BET protein inhibitors prevent TKI-induced drug resistance in solid tumors. Wed, Apr 20, 8:00 AM - 12:00 PM

Abstract #4796: Hu N. et al.,BTK inhibitor BGB-3111 synergizes with lenalidomide in MCL models. Wed, Apr 20, 8:00 AM - 12:00 PM

Abstract #5002: Song X. et al.,Anti-tumor activity of a novel anti-human PD-1 antibody BGB-A317 in mouse models. Wed, Apr 20, 8:00 AM - 12:00 PM

About BeiGene

BeiGene is a global, clinical-stage, research-based biotechnology company focused on targeted and immuno-oncological therapeutics. With a team of over 200 scientists, clinicians and staff, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and a lasting impact on cancer patients.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene’s existing product candidates and research programs.  Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates, the clinical results for its drug candidates, which may not support further development, actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials, BeiGene's ability to achieve market acceptance in the medical community necessary for commercial success, BeiGene's ability to obtain and maintain protection of intellectual property for its technology and drugs, BeiGene's reliance on third parties to conduct preclinical studies and clinical trials, and BeiGene's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the section entitled "Risk Factors" in the final prospectus related to BeiGene's initial public offering filed with the U.S. Securities and Exchange Commission pursuant to Rule 424(b) of the Securities Act of 1933, as amended, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission.  All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.

Investor/Media Contact
Lucy Li, Ph.D.
+1 781-801-1800
[email protected]
[email protected]